Australian Entrepreneur Publicly Discloses Full Process of Using AI to Design mRNA Cancer Vaccines for Pets, Involving 300GB of Genetic Data and Multi-Model Collaboration

Odaily News Australian AI consultancy founder Paul Conyngham posted on X, disclosing the complete technical process of using multiple AI chatbots to design a personalized mRNA cancer vaccine for his pet dog. The dog was diagnosed with malignant mast cell cancer in May 2024. Subsequently, approximately 300GB of data was obtained through whole-genome and RNA sequencing. With the collaborative efforts of ChatGPT, Gemini, and Grok, tasks including target screening, protein structure modeling, and vaccine sequence design were completed. The process ultimately identified a c-KIT gene mutation and screened for 7 neoantigen targets.

The vaccine was prepared by a relevant research team at the University of New South Wales and administered at the University of Queensland's School of Veterinary Science. The overall treatment plan included a combination of the mRNA vaccine, a tyrosine kinase inhibitor, and a PD-1 inhibitor, with the dosing schedule assisted by AI planning. Treatment began in December 2025, and within three months, some tumors showed signs of shrinking. However, some non-responsive lesions still required surgical intervention. Experts pointed out that this case represents a single individual practice and does not yet constitute a universal medical conclusion.